Pfizer’s IBRANCE Demonstrates Significant Efficacy in HR+, HER2+ Metastatic Breast Cancer
Efficacy in HR+, HER2+ MBC:
The Phase 3 PATINA trial showed that adding IBRANCE to standard-of-care therapies significantly improved progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC)13.
PFS Improvement:
The median PFS was 44.3 months for patients treated with IBRANCE in combination with anti-HER2 therapy and endocrine therapy, compared to 29.1 months for those treated with anti-HER2 therapy and endocrine therapy alone1.
Clinical Significance:
This study underscores the potential of IBRANCE as a maintenance therapy in HR+, HER2+ MBC, addressing a significant unmet need in this patient population13.
IBRANCE Mechanism:
IBRANCE is a CDK4/6 inhibitor that works by disrupting the activity of proteins CDK4 and CDK6, which are involved in cell division and growth4.
Regulatory Implications:
The results of the PATINA trial are expected to be discussed with regulatory authorities, potentially leading to an expanded indication for IBRANCE in HR+, HER2+ MBC13.
Sources:
1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ibrancer-combination-standard-care-therapies
3. https://endpts.com/pfizer-shares-positive-phase-3-results-in-breast-cancer-subset/